Tiziana Life Sciences Ltd
corporate_fare Company Profile
Tiziana Life Sciences Ltd (NASDAQ:TLSA) is a publicly traded company in the Life Sciences sector. Wiseek monitors TLSA SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.
Recent high-impact activity:
- Tiziana Life Sciences Completes Dosing in Phase 2a MS Trial; Topline Data Expected Late Q3/Early Q4 2026
- Tiziana Life Sciences Completes Enrollment for Key Phase 2a MS Trial; Topline Data Expected Late Q3 2026
- Tiziana Reports Positive Longer-Term Data for Foralumab in MS Expanded Access Program
- Tiziana Reports Positive Phase 2 PET Imaging Data for Foralumab in Multiple System Atrophy
- Tiziana Life Sciences Faces Going Concern, Secures $8.6M in Insider-Backed Offering to Fund Clinical Trials
Financial Snapshot
Dilution Risk
Low riskFiling-implied dilution signals for TLSA, detected from its recent SEC filings.
Auditors Issue Going Concern Warning · Secured $8.6M in Registered Direct Offering
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →
Insider Transactions
TLSA files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.